MIB Agents Osteosarcoma Alliance

Yesterday, we were joined by Arianexys Aquino-López, MD, PhD, on OsteoBites to discuss, "Repurposing Virus Specific T cells as Immune Therapy for Osteosarcoma". Watch the full episode here: https://lnkd.in/giRnTkqY Dr. Arianexys Aquino-López is an Instructor at the Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine. Dr. Aquino-Lopez is committed to a career as a pediatrician-scientist with a particular interest in improving treatment options for children with cancer through the design of novel immune therapies, including cell therapies and antibody therapies. She is also interested in studying the impact of tumor microenvironment in immune suppression to develop approaches to overcome cancer immune evasion. Witnessing her brother go through pediatric cancer treatment served as an inspiration for her to study ways to improve cancer therapies. #MIBAgents #MakeItBetter #osteosarcoma #OsteoBites #podcast

Yesterday we were joined by Shahana Mahajan, PhD on OsteoBites to discuss, "Repurposing Drugs for Osteosarcoma". Watch the full episode here: https://lnkd.in/gEZ_pUBH Dr. Mahajan earned a Ph.D. from the Indian Institute of Science, a premier Institute in India in the field of Molecular Biology. She did postdoctoral studies at Weill Cornell Medical College in the Department of Pharmacology and at NYU Langone Medical Center in the Department of Biochemistry. She continued her research at NYU Langone Medical Center as a Research Assistant Professor until she joined Hunter College as an Assistant Professor in 2007. At Hunter, she continued her research neuroscience to investigate glutamate-induced excitotoxicity in rat hippocampal neurons. After her lab was lost to Hurricane Sandy, she reinitiated her research in osteosarcoma. In 2015, her lab moved to Belfer Research Building which is a part of Weill Cornell Medical College. She was appointed as an adjunct faculty at Weill Cornell Medical College.  #MIBAgents #MakeItBetter #osteosarcoma #OsteoBites #podcast

TURBO is a virtual international osteosarcoma tumor board designed to bring together multidisciplinary osteosarcoma experts across the globe to review complex cases and share experience and knowledge! By bringing the best minds in osteosarcoma together on a regular basis, TURBO will encourage collaboration and discussion among osteosarcoma experts. With TURBO, oncologists worldwide have access to experienced and expert osteosarcoma clinicians, regardless of institution or geography. PLEASE NOTE: Only physicians may participate in TURBO. MIB Agents is pleased to offer this resource at no cost to physicians or their patients. These are not formal second opinions, but an educational forum. NEXT MEETING: November 6th at 5p ET For more, please visit: https://lnkd.in/gPei8UtR #MIBAgents #MakeItBetter #osteosarcoma #TURBO #tumorboard

Have a compelling topic to share with the osteosarcoma community? We want to hear about it! Starting on October 7th, 2024, MIB Agents is accepting abstract submissions for FACTOR 2025. Abstracts submissions are due online at Proposal Central on January 10, 2025. Abstracts will be considered for oral presentation or poster presentation at FACTOR 2025. For more details on eligibility and the application process, please visit: https://lnkd.in/eEzrWPD6 Please email [email protected] with any questions. #MIBAgents #MakeItBetter #osteosarcoma #FACTOR2025 #F25

OutSmarting Osteosarcoma 2025! OutSmarting Osteosarcoma is an annual award begun in 2017. Since then, MIB Agents has supported 22 investigators and awarded $1,800,000 to support osteosarcoma research. Our 2025 grant cycle will include two funding mechanisms. The OutSmarting Osteosarcoma Hero Award is a $100,000 grant and the OutSmarting Osteosarcoma Young Investigator (YI) Hope Award is a $50,000 grant. The Letters of Intent (LOI) submission period will open on September 27, 2024. LOIs are due by October 25, 2024 at 11:59pm ET. Applicants who submit a LOI and are approved will then be invited via email to submit a full application by January 26, 2025. Questions? Email [email protected] or visit https://lnkd.in/gk9h4WSp

Yesterday, we wete joined by Joanne Tuohy, DVM, PhD on OsteoBites to discuss, "The ablative and immunomodulatory effects of histotripsy treatment in osteosarcoma". Watch the full episode here: https://lnkd.in/g_Hn8dCa Joanne Tuohy is an associate professor of surgical oncology at the Animal Cancer Care and Research Center at Virginia Tech. Her research focuses on developing a novel tumor ablation technique, histotripsy, as a non-invasive method of tumor elimination, and as an immunomodulatory therapy that can induce synergism with immunotherapies. Joanne Tuohy has focused her work primarily on osteosarcoma to improve treatments and disease outcomes for patients. Her tumor ablation research is also expanding to include other tumor types such as oral tumors. Joanne Tuohy went to Colorado State University for her DVM education, followed by a rotating internship and surgical residency at North Carolina State University. She also completed a Comparative Biomedical Sciences PhD program in Immunology at North Carolina State University. Joanne Tuohy completed her training as a Fellow in Surgical Oncology at Colorado State University. Joanne Tuohy started her faculty career at Virginia Tech in 2019 and is a member of the Animal Cancer Care and Research Center at Virginia Tech. The Center offers comprehensive cancer care to veterinary patients, and hosts veterinary clinical trials for dogs and cats with cancer. #MIBAgents #MakeItBetter #osteosarcoma #OsteoBites #podcast

MIB’s YouTube channel crossed 1k subscribers! 🎙️100+ OsteoBites podcast episodes featuring the leading experts in osteosarcoma. 🎙️ AYA osTEAo podcast all feat AYA Cancer patients with 20k+ views each month. 📹 An audio/visual library of educational and informative videos, it’s an evolving learning space for the osteosarcoma community! #osteosarcoma #1kCreator #MakeItBetter #OsteoBites #BetterTogether MIB YouTube: https://lnkd.in/gYvJ7E2N

Yesterday, we were joined by Troy McEachron, PhD on OsteoBites to discuss, "Molecular and Cellular Deconstruction of Metastatic Osteosarcoma". Watch the full episode here: https://lnkd.in/gSaNGH68 Dr. McEachron earned his doctorate in Molecular and Cellular Pathology from the University of North Carolina at Chapel Hill in 2011. He completed postdoctoral fellowships at St. Jude Children’s Research Hospital and at the Translational Genomics Research Institute. In 2016, Dr. McEachron joined the faculty of the Keck School of Medicine at the University of Southern California as an Assistant Professor in the Department of Translational Genomics (primary appointment) and the Department of Pediatrics (secondary appointment). Dr. McEachron joined the Pediatric Oncology Branch in 2021. In addition to conducting impactful research, Dr. McEachron is passionate about the importance of representation and diversifying the trainee and workforce landscape in biomedical research. #MIBAgents #MakeItBetter #osteosarcoma #OsteoBites #podcast

🙌 Team MIB 🙌

MIB Agents Founder and the MIB Junior Advisory Board: Story Below